Biological markers for longevity and diseases and uses thereof

• US 8,703,496 B2
• Filed: 03/15/2013
• Issued: 04/22/2014
• Est. Priority Date: 03/20/2003
• Status: Expired due to Fees

• Current Assignee: Albert Einstein College of Medicine (Yeshiva University)
• Original Assignee: Albert Einstein College of Medicine of Yeshiva University
• Inventors: Barzilai, Nir, Lipton, Richard B.
• Primary Examiner(s): KAM, CHIH MIN
• Application Number:
  US13/832,832
• Publication Number:
  US 20130244333A1
• Time in Patent Office: 403 Days
• Field of Search: 436/71, 530/359
• US Class Current: 436/71
• CPC Class Codes: C12Q 1/48 involving transferase
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: G01N 2800/04 Endocrine or metabolic disorders
• CPC Class Codes: G01N 2800/042 Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
• CPC Class Codes: G01N 2800/2814 Dementia; Cognitive disorders
• CPC Class Codes: G01N 2800/2871 Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
• CPC Class Codes: G01N 2800/32 Cardiovascular disorders
• CPC Class Codes: G01N 2800/321 Arterial hypertension
• CPC Class Codes: G01N 2800/324 Coronary artery diseases, e.g. angina pectoris, myocardial infarction
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere
• CPC Class Codes: G01N 33/92 involving lipids, e.g. cholesterol , lipoproteins, or their receptors steroid hormones G01N33/743

Abstract

This invention provides methods of using of the sizes and levels of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles, the −641 allele of the promoter of the gene encoding apolipoprotein C-3 (APOC-3), the 405 allele of the gene encoding cholesteryl ester transfer protein (CETP), and plasma levels of insulin-like growth factor-1 (IGF-1), adiponectin, CETP and APOC-3, for determining and increasing an individual'"'"'s likelihood of longevity and of retaining cognitive function during aging, and for determining and decreasing an individual'"'"'s likelihood of developing a cardiovascular-, metabolic- or age-related disease.

Claims

1. A method for identifying a compound for decreasing hypertension and increasing insulin sensitivity in a subject, the method comprising

determining whether or not a compound inhibits the activity of cholesteryl ester transfer protein (CETP), wherein a compound that inhibits the activity of CETP is a candidate compound for decreasing hypertension and increasing insulin sensitivity, and

determining whether or not the compound that inhibits the activity of CETP decreases hypertension and increases insulin sensitivity in a subject,

wherein the compound identified decreases hypertension and increases insulin sensitivity in a subject.

2. A method for identifying a compound for decreasing hypertension and increasing insulin sensitivity in a subject, the method comprising

identifying a compound that inhibits the activity of cholesteryl ester transfer protein (CETP), and

determining whether or not the compound that inhibits CETP decreases hypertension and increases insulin sensitivity in a subject,

wherein the compound identified decreases hypertension and increases insulin sensitivity in a subject.

3. A method for identifying a compound for increasing insulin sensitivity in a subject, the method comprising

determining whether or not a compound inhibits the activity of cholesteryl ester transfer protein (CETP), wherein a compound that inhibits the activity of CETP is a candidate compound for increasing insulin sensitivity, and

determining whether or not the compound that inhibits the activity of CETP increases insulin sensitivity in a subject,

wherein the compound identified increases insulin sensitivity in a subject.

4. A method for identifying a compound for increasing insulin sensitivity in a subject, the method comprising

identifying a compound that inhibits the activity of cholesteryl ester transfer protein (CETP), and

determining whether or not the compound that inhibits CETP increases insulin sensitivity in a subject,

wherein the compound identified increases insulin sensitivity in a subject.